Kenvue Inc. $KVUE Shares Sold by Kinloch Capital LLC

Kinloch Capital LLC lessened its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 21.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 121,888 shares of the company’s stock after selling 32,327 shares during the quarter. Kinloch Capital LLC’s holdings in Kenvue were worth $2,103,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Physician Wealth Advisors Inc. boosted its stake in shares of Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after buying an additional 618 shares during the last quarter. Elyxium Wealth LLC acquired a new stake in Kenvue in the fourth quarter valued at $26,000. SBI Securities Co. Ltd. boosted its stake in Kenvue by 82.4% during the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after acquiring an additional 1,027 shares during the last quarter. Leonteq Securities AG bought a new position in Kenvue during the 4th quarter valued at $45,000. Finally, DV Equities LLC acquired a new position in Kenvue during the 4th quarter worth $46,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

KVUE has been the subject of several research analyst reports. Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday. Argus raised shares of Kenvue to a “hold” rating in a research report on Friday, March 6th. Barclays decreased their price target on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 14th. Zacks Research raised Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. Finally, UBS Group cut their price objective on Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 7th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $19.33.

Insiders Place Their Bets

In related news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.59% of the stock is currently owned by company insiders.

Kenvue Stock Up 0.9%

KVUE stock opened at $18.17 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $22.87. The firm has a fifty day moving average price of $17.52 and a two-hundred day moving average price of $17.57. The firm has a market cap of $34.88 billion, a price-to-earnings ratio of 21.37, a PEG ratio of 1.37 and a beta of 0.54.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The company had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $3.84 billion. During the same period in the prior year, the company earned $0.24 earnings per share. The firm’s revenue was up 4.5% compared to the same quarter last year. Research analysts predict that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were given a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.6%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s dividend payout ratio is currently 97.65%.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.